ZyVersa Therapeutics, Inc. (ZVSA) reported Loss for second quarter of -$2.211 million
The company's bottom line came in at -$2.211 million, or -$0.46 per share. This compares with -$2.763 million, or -$3.31 per share, last year.
ZyVersa Therapeutics, Inc. earnings at a glance (GAAP) :
-Earnings: -$2.211 Mln. vs. -$2.763 Mln. last year.-EPS: -$0.46 vs. -$3.31 last year.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.